Champions Oncology Overview

  • Year Founded
  • 1985

Year Founded

  • Status
  • Public

  • Employees
  • 214

Employees

  • Stock Symbol
  • CSBR

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.34
  • (As of Friday Closing)

Champions Oncology General Information

Description

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.

Contact Information

Formerly Known As
Champions Biotechnology, Champions Sports
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • One University Plaza
  • Suite 307
  • Hackensack, NJ 07601
  • United States
+1 (240)
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • One University Plaza
  • Suite 307
  • Hackensack, NJ 07601
  • United States
+1 (240)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Champions Oncology Stock Performance

As of 20-Nov-2026, Champions Oncology’s stock price is $4.34. Its current market cap is $60.4M with 13.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.34 $4.40 $4.34 - $8.31 $60.4M 13.9M 9.7K -$0.08

Champions Oncology Financials Summary

As of 31-Jul-2026, Champions Oncology has a trailing 12-month revenue of $60.7M.

In Thousands,
USD
TTM 31-Jul-2026 FY 2026 30-Apr-2026 FY 2025 30-Apr-2025 FY 2024 30-Apr-2024
EV 74,239 80,627 102,097 69,204
Revenue 60,661 59,425 56,944 50,155
EBITDA 441 448 6,266 (5,441)
Net Income (1,073) (1,175) 4,701 (7,276)
Total Assets 33,290 26,989 32,344 26,132
Total Debt 10,521 4,512 6,105 7,430
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Champions Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Champions Oncology‘s full profile, request access.

Request a free trial

Champions Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technolog
Discovery Tools (Healthcare)
Hackensack, NJ
214 As of 2026

Ramat Gan, Israel
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Champions Oncology Competitors (13)

One of Champions Oncology’s 13 competitors is Eocene (Drug Discovery), a Corporation company based in Ramat Gan, Israel.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eocene (Drug Discovery) Corporation Ramat Gan, Israel
Amryt Pharma Corporate Backed or Acquired London, United Kingdom
Exscientia Formerly VC-backed Oxford, United Kingdom
BPS Bioscience Corporation San Diego, CA
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom
You’re viewing 5 of 13 competitors. Get the full list »

Champions Oncology Patents

Champions Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025174721-A1 Vps4 inhibitors Pending 12-Feb-2024
US-20260232824-A1 Anti-cd180 binding molecules and uses thereof Pending 03-Feb-2023
WO-2024163920-A2 Anti-cd180 binding molecules and uses thereof Inactive 03-Feb-2023
WO-2024163920-A3 Anti-cd180 binding molecules and uses thereof Inactive 03-Feb-2023
CA-2995574-A1 Personalized treatment of diseases and disorders Inactive 13-Aug-2015 C12Q1/6886
To view Champions Oncology’s complete patent history, request access »

Champions Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Champions Oncology Acquisitions (1)

Champions Oncology’s most recent deal was a Merger/Acquisition with Biomerk for . The deal was made on 18-May-2007.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Biomerk 18-May-2007 Merger/Acquisition Drug Discovery
To view Champions Oncology’s complete acquisitions history, request access »

Champions Oncology ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Champions Oncology’s complete esg history, request access »

Champions Oncology Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Corellia AI Rockville, MD 2020

Champions Oncology FAQs

  • When was Champions Oncology founded?

    Champions Oncology was founded in 1985.

  • Where is Champions Oncology headquartered?

    Champions Oncology is headquartered in Hackensack, NJ.

  • What is the size of Champions Oncology?

    Champions Oncology has 214 total employees.

  • What industry is Champions Oncology in?

    Champions Oncology’s primary industry is Discovery Tools (Healthcare).

  • Is Champions Oncology a private or public company?

    Champions Oncology is a Public company.

  • What is Champions Oncology’s stock symbol?

    The ticker symbol for Champions Oncology is CSBR.

  • What is the current stock price of Champions Oncology?

    As of 20-Nov-2026 the stock price of Champions Oncology is $4.34.

  • What is the current market cap of Champions Oncology?

    The current market capitalization of Champions Oncology is $60.4M.

  • What is Champions Oncology’s current revenue?

    The trailing twelve month revenue for Champions Oncology is $60.7M.

  • Who are Champions Oncology’s competitors?

    Eocene (Drug Discovery), Amryt Pharma, Exscientia, BPS Bioscience, and Sygnature Discovery are some of the 13 competitors of Champions Oncology.

  • What is Champions Oncology’s annual earnings per share (EPS)?

    Champions Oncology’s EPS for 12 months was -$0.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process